Melanin production in medullary thyroid carcinoma.

Histopathology

Department of Pathology, Institut Salah Azaiez, Tunis, Tunisia.

Published: December 1995

A case of melanin-producing medullary thyroid carcinoma is reported in a 51-year-old man. Histologically, the tumour had a typical pattern of medullary thyroid carcinoma with numerous scattered pigmented cells which contained large amounts of melanin pigment as confirmed by bleached Fontana-Masson stain. Immunohistochemical staining revealed positivity of almost all tumour cells for calcitonin and chromogranin, whereas S-100 protein and HMB-45 staining was positive only in the pigmented tumour cells. This finding confirms the ability of medullary thyroid carcinoma cells to have multidirectional differentiation, although melanocytic differentiation remains an exceptional phenomenon.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2559.1995.tb00329.xDOI Listing

Publication Analysis

Top Keywords

medullary thyroid
16
thyroid carcinoma
16
tumour cells
8
melanin production
4
medullary
4
production medullary
4
thyroid
4
carcinoma
4
carcinoma case
4
case melanin-producing
4

Similar Publications

Computational insights into the aggregation mechanism of human calcitonin.

Int J Biol Macromol

January 2025

School of Physical Science and Technology, Ningbo University, Ningbo 315211, China; Department of Physics and Astronomy, Clemson University, Clemson, SC 29634, United States. Electronic address:

Human calcitonin (hCT) is a peptide hormone that regulates calcium homeostasis, but its abnormal aggregation can disrupt physiological functions and increase the risk of medullary thyroid carcinoma. To elucidate the mechanisms underlying hCT aggregation, we investigated the self-assembly dynamics of hCT segments (hCT, hCT, and hCT) and the folding and dimerization of full-length hCT through microsecond atomistic discrete molecular dynamics (DMD) simulations. Our results revealed that hCT and hCT predominantly existed as isolated monomers with transient small-sized oligomers, indicating weak aggregation tendencies.

View Article and Find Full Text PDF

Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials.

Am J Med Genet C Semin Med Genet

January 2025

Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

RET gene is a driver of thyroid cancer (TC) tumorigenesis. The incidence of TC has increased worldwide in the last few decades, both in medullary and follicular-derived subtypes. Several drugs, including multikinase and selective inhibitors, have been explored.

View Article and Find Full Text PDF

Thyroid surgery in pediatric age: a ten-year experience at a single center and literature review.

J Pediatr Endocrinol Metab

January 2025

Department of Otolaryngology, Pendik Training and Research Hospital, Marmara University, Istanbul, Türkiye.

Objectives: Surgery interventions for thyroid disorders are rare in pediatric population. This study aims to present our institution's 10-year experience regarding the surgical treatment and outcomes of thyroid pathologies in children and review the literature.

Methods: All pediatric patients who underwent thyroid surgery at our institution from April 2013 to October 2023 were retrospectively reviewed.

View Article and Find Full Text PDF

Background: The International Medullary Thyroid Carcinoma Grading System (IMTCGS) was recently introduced in medullary thyroid carcinoma (MTC). This study aimed to assess the predictive value of the IMTCGS for disease response and survival, and compare its predictive ability with that of other traditional risk factors in a Chinese MTC cohort.

Methods: The data of 137 MTC patients undergoing initial surgery between January 2004 and June 2023 were included for analysis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!